[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536720":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":51,"collaborators":28,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":28,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":28,"enrollmentInfo":63,"targetDuration":28,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":41,"whyStopped":28,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Cosmetique Active International","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"mild to moderate melasma","EXPERIMENTAL","adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)",[13],"Other: serum formula 2039125 03",{"label":15,"type":10,"description":16,"interventionNames":17},"mild to moderate acne induced PIHP","adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"solar lentigo","adult patients suffering from solar lentigo with a pigmentation score \\> 5",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"OTHER","serum formula 2039125 03","application twice a day of the tested product (in the morning and evening) to the face for 3 months",[15,9,19],null,[30],{"name":31,"affiliation":32,"role":33},"Sergio Schalka","Medcin Instituto da Pele Ltda","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":28,"email":38},"CONTACT","+55 (11) 3683-5366","sergio.schalka@medcin.com.br",[40],{"facility":32,"status":41,"city":42,"state":28,"zip":28,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":28},"RECRUITING","Osasco","Brazil","BR",{"type":46,"coordinates":47},"Point",[48,49],-46.79167,-23.5325,{"lat":49,"lon":48},{"type":52,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100536720","efficacy-and-tolerability-of-the-tested-formula-after-3-months-in-treatment-of-facial-hyperpigmentation-of-3-origins-100536720",false,"NCT06268496","Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins","Evaluation of the Efficacy and Tolerability of the Tested Formula BID After 3 Months in the Treatment of Facial Hyperpigmentation of 3 Origins: Melasma, Acne Induced Post-Inflammatory Hyperpigmentation and Solar Lentigo","Inclusion Criteria:\n\n* all phototypes\n* only one of the following pigmentary conditions on the face: epidermal or mixed, mild to moderate melasma; mild to moderate acne-induced PIHP; solar lentigo\n* female patient of childbearing potential must use one of the reliable methods of contraception and agree not to change it during the study\n* patient agreeing not to be exposed to ultraviolet radiation (UV), natural (sun) or artificial (tanning salon), during the study\n\nExclusion Criteria:\n\n* female patient who gave birth less than 3 months prior to Day 0, who is pregnant, breast-feeding or who plans to become pregnant during the study\n* male patient with beard or facial hair, which would interfere with clinical evaluation or clinical procedure baseline)\n* patient with any inflammatory dermatosis of the face such as seborrheic dermatitis, rosacea etc.\n* severe melasma, dermal melasma\n* patient with facial pigmentary disorders other than those described in inclusion criteria\n* patient who has used topical depigmenting agents such as hydroquinone and derivatives, glycolic acid, kojic acid, retinoids and derivatives, azelaic acid, niacinamide within 1 month prior to Day 0\u002FBaseline visit\n* patient who has used systemic treatments such as tranexamic acid and oral melatonin within 1 month prior to Day 0\u002FBaseline visit;\n* patient who has used drugs inducing pigmentation such as tetracyclines, fluoroquinolones, antiepileptics within 1 month prior to Day 0\u002FBaseline visit",true,"ALL","18 Years",{"count":64,"type":65},60,"ESTIMATED","INTERVENTIONAL",[68],"NA","The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.",[71],"Hyperpigmentation",[73,74,75,19],"facial hyperpigmentation","melasma","acne induced PIHP","2024-07-10",{"date":78,"type":79},"2024-07-12","ACTUAL",{"date":81,"type":79},"2024-03-14",{"date":83,"type":65},"2024-07",{"name":5,"class":6},1]